Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Phathom Pharmaceuticals, Inc. (PHAT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Second Quarter 2023 Results"
05/10/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports First Quarter 2023 Results"
02/28/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
11/09/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates"
05/10/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates"
05/11/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials"
08/06/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports First Quarter 2020 Results Florham Park, N.J., May 12, 2020 - Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2020. “As previously announced, we temporarily paused new patient randomization in our PHALCON-HP and PHALCON-EE Phase 3 studies of vonoprazan due to the COVID-19 pandemic during the first quarter of 2020,” said Terrie Curran, President and Chief Executive Officer of Phathom Pharmaceuticals. “Prior to the pause, we were pleased with trial enrollment and subsequently have been working with our clinical trial sites on a plan to restart randomization when safe to do so. We are..."
03/19/2020 8-K Quarterly results
Docs: "Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates"
11/25/2019 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy